People living with Type 2 diabetes face a significantly higher risk of developing severe, life-threatening complications from dengue infection, according to a new review by leading medical specialists. The study found that individuals with pre-existing diabetes are almost three times more likely to develop severe dengue compared to those without the condition. This critical finding emphasizes the urgent need for integrated public health strategies.
Diabetes Weakens Dengue Defense
The review paper, led by diabetologist Dr. Jothydev Kesavadev and co-authored by several prominent diabetes experts, including Dr. Niti Pall, President-Elect of the International Diabetes Federation, Europe, is set for publication in the International Journal of Diabetes & Technology. Its findings were shared with the media on Sunday, July 19, 2026. The authors explain that persistently high blood sugar, a hallmark of Type 2 diabetes, impairs the body's immune function and damages blood vessels. This makes diabetic patients more vulnerable to severe dengue infection.[tribuneindia+3]
Once infected, these patients are more prone to an exaggerated inflammatory response, often called a "cytokine storm." This intense reaction can lead to severe conditions like dengue hemorrhagic fever, internal bleeding, and potentially fatal dengue shock syndrome, marked by a sharp drop in blood pressure. Beyond increased severity, diabetes is also linked to an almost four times greater risk of death from dengue. Research into how diabetes impacts dengue's pathophysiology suggests that poor glycemic control and altered platelet activity play a role. Hyperglycemia can lead to immune response dysfunction, suppressing cytokine production and impairing immune cell function. Increased platelet activity in diabetic patients might also hinder the interferon pathway, potentially boosting dengue virus replication.[tribuneindia+5]
Call for Vaccination Integration
Given these heightened risks, the review strongly recommends incorporating dengue vaccination into routine diabetes care, especially for vulnerable populations in regions where dengue is common. Dr. Kesavadev stated that people with diabetes represent one of the most vulnerable groups during dengue outbreaks. He added that integrating dengue vaccination into regular diabetes management could significantly reduce severe illness and hospitalizations for high-risk individuals. This approach aims to strengthen infectious disease prevention alongside chronic disease management.[tribuneindia+3]
The TAK-003 dengue vaccine, marketed globally as Qdenga by Takeda, shows promising results. Multi-year clinical studies cited by the authors indicate that this vaccine has reduced dengue-related hospitalizations by 84% to 90%, offering robust protection against severe disease. The vaccine is effective against all four dengue virus serotypes and can be administered regardless of a person's prior dengue infection status, eliminating the need for pre-vaccination blood tests. The vaccine has already received approval in 42 countries.[uniindia+2]
Global Burden of Dengue and Diabetes
Dengue fever continues to pose a major global public health challenge, with its incidence dramatically increasing in recent decades. In 2024 alone, the World Health Organization (WHO) reported over 14.4 million dengue cases worldwide, including 52,738 severe cases and 11,201 deaths. Approximately 4 billion people, nearly half of the global population, live in areas at risk of dengue infection.[who+2]
The global burden of Type 2 diabetes is also substantial and growing. An estimated 462 million individuals worldwide are affected by Type 2 diabetes, representing 6.28% of the global population. Other estimates suggest this number was 529 million in 2021, with projections indicating it could reach 1.3 billion by 2050. The International Diabetes Federation also reports that 11.1% of adults aged 20-79 years currently live with diabetes, a figure expected to rise to one in eight adults, or approximately 853 million, by 2050.[pmc+2]
Rising Comorbidity Concerns
The intersection of these two epidemics creates a serious public health threat. Countries with the highest numbers of reported dengue cases are also projected to see a significant rise in diabetes prevalence by 2050. For the 20 countries with the highest predicted dengue cases in 2019, a median increase of 61.8% in diabetes cases is projected by 2050. This alarming trend will likely lead to a greater incidence of dengue-diabetes comorbidity, consequently increasing severe dengue cases and related mortality.[academic+2]
Healthcare providers and policymakers in dengue-endemic regions, and those with rising diabetes rates, must recognize this escalating risk. Efforts should focus on updating clinical guidelines for managing comorbid patients, educating diabetic individuals about dengue risks and symptoms, and improving access to vector control measures. Monitoring blood sugar levels closely during any fever episode is crucial for diabetic patients, as infections can cause wide fluctuations in glucose levels, further complicating their condition and potentially leading to severe outcomes like diabetic ketoacidosis or kidney failure. Early detection and tailored management strategies are essential to reduce morbidity and mortality in this high-risk group.[academic+2]
